Overview

Lidocaine Infusion in Pancreatic Cancer

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for all types of pancreatic cancer. A prospective randomized controlled double blinded trial design will be used for the proposed study.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Illinois at Chicago
Treatments:
Lidocaine